FDA Approves First Drug to Image Tau Pathology in Patients B
U.S. Food and Drug Administration approved Tauvid (flortaucipir F18) for intravenous injection, the first drug used to help image a distinctive characteristic of Alzheimer’s disease in the brain called tau pathology.

• Tauvid is a radioactive diagnostic agent for adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.

• Tauvid is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs), a primary marker of Alzheimer’s disease.

• Two proteins – tau and amyloid – are recognized as hallmarks of Alzheimer’s disease. In patients with Alzheimer’s disease, pathological forms of tau proteins develop inside neurons in the brain, creating neurofibrillary tangles.

• After Tauvid is administered intravenously, it binds to sites in the brain associated with this tau protein misfolding. The brain can then be imaged with a PET scan to help identify the presence of tau pathology.

• The most common adverse reactions in patients using Tauvid - headache, injection site pain, and increased blood pressure.

• Tauvid is not indicated for use in the evaluation of patients for chronic traumatic encephalopathy (CTE).

• The FDA granted approval of Tauvid to Avid Radiopharmaceuticals, Inc.

Source: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-image-tau-pathology-patients-being-evaluated-alzheimers-disease
A●●a S●●●n J●●e and 1 others like this